US-based Johnson & Johnson has signed an agreement to acquire a privately held clinical stage biopharmaceutical company, Alios BioPharma, for $1.75bn in cash.

Based in California, US, Alios develops therapies for the treatment of viral diseases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The discovery and development platform of Alios include chemical library of nucleoside analogues, as well as virology-based screening systems.

Janssen Pharmaceutical Companies of Johnson & Johnson research and development global head William Hait said: "We are excited that this acquisition will enable us to explore treatment options for a number of viral infections, including RSV, the last of the major paediatric diseases with no available preventive therapy.

"AL-8176 complements our existing early stage portfolio for RSV, which aims to prevent and treat this disease, the leading cause of acute lower respiratory infection in children under the age of five."

"As part of the deal, Johnson & Johnson will acquire Alios’s therapeutics portfolio, including the compound AL-8176."

As part of the deal, Johnson & Johnson will acquire Alios’s therapeutics portfolio, including the compound AL-8176.

Currently, Alios is carrying out Phase II trials for AL-8176, to treat infants with respiratory syncytial virus (RSV).

The company is developing therapeutics for viral infections, which are caused by respiratory syncytial virus, influenza, rhinovirus, coronavirus and HCV.

Alios BioPharma president and CEO Lawrence Blatt said: "We are so pleased to be joining the Janssen Pharmaceutical Companies of Johnson & Johnson, who have an impressive track record of bringing breakthrough drugs for viral diseases to market."

The deal is expected to be completed in the fourth quarter of this year, subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.

Image: Johnson & Johnson headquarters in New Brunswick, New Jersey. Photo: courtesy of Nikopoley.